Immunohistochemical analysis of CD138/HUWE1 and CD138/MYC validated HUWE1 knockdown in vivo and demonstrated reduction in MYC expression and tumor burden 13 days post-treatment with doxycycline, lenalidomide or a combination of both (Fig. 6f). This evidence concerns the gene MYC and neoplasm.